Edesa Historical Income Statement
| EDSA Stock | USD 4.36 0.04 0.91% |
Historical analysis of Edesa Biotech income statement accounts such as Selling General Administrative of 3.6 M or Other Operating Expenses of 7.3 M can show how well Edesa Biotech performed in making a profits. Evaluating Edesa Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Edesa Biotech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Edesa Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edesa Biotech is a good buy for the upcoming year.
Edesa |
About Edesa Income Statement Analysis
Edesa Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Edesa Biotech shareholders. The income statement also shows Edesa investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Edesa Biotech Income Statement Chart
Edesa Biotech Income Statement is one of the three primary financial statements used for reporting Edesa's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Edesa Biotech revenue and expense. Edesa Biotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Edesa Biotech's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 1 M, whereas Depreciation And Amortization is forecasted to decline to about 200.4 K. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Edesa Biotech. It is also known as Edesa Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Edesa Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 1 M, whereas Depreciation And Amortization is forecasted to decline to about 200.4 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 118.2K | 183.5K | 165.1K | 156.9K | Research Development | 13.3M | 4.8M | 5.5M | 4.3M |
Edesa Biotech income statement Correlations
Click cells to compare fundamentals
Edesa Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edesa Biotech income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 57.6K | 10.3M | 780.3K | 183.5K | 211.0K | 200.4K | |
| Interest Expense | 56.8K | 95.0K | 116.9K | 822.7K | 946.1K | 993.4K | |
| Selling General Administrative | 3.4M | 5.7M | 5.0M | 4.4M | 5.1M | 3.6M | |
| Other Operating Expenses | 6.7M | 13.3M | 17.6M | 9.2M | 10.6M | 7.3M | |
| Operating Income | (6.4M) | (23.7M) | (18.4M) | (9.2M) | (8.3M) | (8.7M) | |
| Ebit | (6.4M) | (23.7M) | (18.4M) | (9.2M) | (8.3M) | (8.7M) | |
| Ebitda | (6.3M) | (13.3M) | (17.6M) | (9.2M) | (8.3M) | (8.7M) | |
| Total Operating Expenses | 6.7M | 13.3M | 17.6M | 9.2M | 10.6M | 6.8M | |
| Income Before Tax | (6.4M) | (13.3M) | (17.5M) | (8.4M) | (7.5M) | (7.9M) | |
| Total Other Income Expense Net | 37.4K | 10.3M | 822.7K | 849.1K | 976.5K | 1.0M | |
| Net Income | (6.4M) | (13.3M) | (17.5M) | (8.4M) | (7.5M) | (7.9M) | |
| Gross Profit | 311.2K | (118.8K) | (118.2K) | (183.5K) | (165.1K) | (156.9K) | |
| Research Development | 3.3M | 17.9M | 13.3M | 4.8M | 5.5M | 4.3M | |
| Cost Of Revenue | 17.6K | 118.8K | 118.2K | 183.5K | 165.1K | 156.9K | |
| Interest Income | 37.8K | 11.2K | 63.5K | 289.8K | 260.9K | 273.9K | |
| Net Income Applicable To Common Shares | (3.1M) | (6.4M) | (13.3M) | (17.5M) | (15.8M) | (15.0M) | |
| Net Income From Continuing Ops | (6.4M) | (13.3M) | (17.5M) | (8.4M) | (7.5M) | (7.9M) | |
| Reconciled Depreciation | 57.6K | 118.8K | 118.2K | 183.5K | 165.1K | 97.2K | |
| Net Interest Income | 37.8K | 11.2K | 63.5K | 289.8K | 333.3K | 350.0K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Edesa Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Edesa Biotech's short interest history, or implied volatility extrapolated from Edesa Biotech options trading.
Pair Trading with Edesa Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.56) | Return On Equity (0.96) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.